Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
Open accessThe DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index; 6 of the 44 sources its claims cite were checked for support.
Abstract
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.
Overview
CoChat Summary
## TL;DR
Lutathera® ([177Lu]Lu-DOTA-TATE) is presented as the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy (PRRT) for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors. The paper summarizes its mechanism, indication, dosing, manufacturing, and the clinical trial results that supported approval.
## Key findings
- Lutathera® was approved by the EMA in 2017 and the FDA in 2018; the paper also notes Canadian approval in 2019.
- Its active ingredient is [177Lu]Lu-DOTA-TATE, which combines lutetium-177 with the somatostatin analogue DOTA-TATE to target SSTR-expressing tumor cells and cause DNA single- and double-strand breaks.
- The recommended treatment schedule is four infusions of 7.4 GBq every 8 weeks; intervals may be extended to 16 weeks if dose-modifying toxicity occurs.
- In the NETTER-1 phase III trial (229 patients), progression-free survival favored [177Lu]Lu-DOTA-TATE plus octreotide LAR over high-dose octreotide LAR: 65% vs 11% of patients were progression-free at 20 months (p < 0.0001), median PFS was not reached vs 8.5 months, and objective response rate was 18% vs 3% (p < 0.001).
## Methods
- Narrative review/overview of Lutathera® covering chemical properties, clinical indication, application, pharmacology/pharmacokinetics, manufacturing, and regulatory status.
- Draws on published clinical studies and product monographs, including the Erasmus phase I/II study (1,214 patients) and the NETTER-1 phase III trial (229 patients).
- Summarizes reported trial endpoints and pharmacokinetic/dosimetry data from the cited studies rather than presenting new original analyses.
## Limitations
- The paper does not report any new original experimental or clinical data; it synthesizes prior literature and regulatory documents.
- The text makes evident that some sections are only brief summaries and refer readers to product monographs or cited studies for details; this limits methodological depth and reproducibility of the review’s own synthesis.
- Not stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
5 Valid · 0 Not valid · 33 Not checked · 1 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The positive results of the multicenter phase-III clinical trial [16], NETTER-1, comparing the treatment with [177Lu]Lu-DOTA-TATE to the treatment with high doses of octreotide LAR, paved the way for its approval by national and international medicines agencies in America and Europe.”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 4. Conclusions
What the sources say
- Partly supportedcites [16] Strosberg, 2017, NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 3. Medicinal and Pharmaceutical Overview > 3.3. Pharmacology and Pharmacokinetics In a study by Reubi et al. [29], the SSTR subtype affinity profile of a number of somatostatin analogues was investigated, showing, e.g., that DOTA-TATE exhibits high affinity for human SSTR2 (IC50 of 1.5 ± 0.4 nM) with much less binding affinity for all other human SSTRs. Complexing this peptide with yttrium resulted in a comparable binding affinity profile and complexing with gallium in an even higher affinity for SSTR2 (IC50 of 0.2 ± 0.04 nM). [177Lu]Lu-DOTA-TATE shows high binding affinity for SSTR2 as well, and therefore binds to malignant cells with an upregulation of SSTR2 [8]. Upon binding to the receptor, the radiolabeled peptide becomes internalized into the cell and the β particle emission of 177Lu induces DNA single- and double-strand breaks, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions [8]. Figure 2 gives a simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE. Due to the range of the β particles in comparison to the diameter of a cell, the emitted β particles traverse several cells (10–1000) [30]. This effect has been termed “cross-fire effect” and is responsible for the possible destruction of multiple cells in the vicinity of the tracer-accumulating cell [31]. Using β particle emitters, the cross-fire effect is critical for the improvement of tumor dose homogeneity and for ensuring a sufficient dose for each cell [32]. Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31]. Owing to the nanomolar concentration (10 µg/mL; 6.3 × 10−3 nM) of the peptide in the sterile injection solution [8], no clinically relevant pharmacodynamic effects are expected. The pharmacokinetic properties of Lutathera® are described in the product monographs [8,27]. [177Lu]Lu-DOTA-TATE is immediately and completely bioavailable through i. v. injection and clears rapidly from blood. The effective half-life in blood in a study with 31 patients was determined to be 0.31 ± 0.13 h [33]. The effective blood elimination half-life is 3.5 ± 1.4 h [26]. Studies using non-radioactive [175Lu]Lu-DOTA-TATE showed that protein binding to human plasma is ca. 50% and that transchelation of lutetium to serum proteins is not occurring. Four hours after administration, [177Lu]Lu-DOTA-TATE shows uptake in kidneys, tumoral lesions, liver, and spleen, and in some patients, additionally in the pituitary gland and thyroid. Kidney uptake can be decreased by co-administration of amino acids (see above), which reduces the re-absorption of the radiopharmaceutical through the proximal tubules [34]. This is mandatory because the compound is primarily eliminated through the renal system. Data from the Erasmus phase-I/-II and NETTER-1 phase-III trials indicate that ca. 60% of the radiopharmaceutical is eliminated in the urine within 24 h post injection (p. i.) and ca. 65% within 48 h p. i. Metabolism of [177Lu]Lu-DOTA-TATE is negligible, as shown by radio-HPLC analysis of urine samples collected 48 h p. i. Radiation dosimetry of [177Lu]Lu-DOTA-TATE has been evaluated in 20 patients in clinical studies [15,27]. The critical organ is the bone marrow. However, with the recommended cumulative dose of 29.6 GBq (4 × 7.4 GBq), neither correlation of hematological toxicity with total administered radioactivity nor with bone marrow absorbed dose has been observed. The kidney is not a critical organ when co-administration of appropriate amino acids is conducted. The median radiation dose to the kidneys can be reduced by 47% (34% to 59%) with co-administration of amino acids [26]. Table 1 summarizes estimated radiation absorbed doses for Lutathera® in the NETTER-1 trial for main organs [26,27].
What the sources say
- Supportedcites [31] Haberkorn, 2017, The Future of Radioligand Therapy: α, β, or Both?, J. Nucl. Med. source
The discussion of the radiation-induced bystander effect (p. 1) explicitly defines it as neighboring cells that were not directly exposed to ionizing radiation behaving as though they were exposed. The Figure 1 caption (p. 2) likewise describes effects on neighboring, unexposed cells. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim could be matched to a paper, so there is nothing to check it against.
In the paper
“The clinical indication of Lutathera® is the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2 grade) SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults [15,27].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 3. Medicinal and Pharmaceutical Overview > 3.1. Clinical Indication
What the sources say
- Not matchedcites [15] (2019, April 23). Lutathera® Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf.
We searched by its title and found no matching paper.
- Not matchedcites [27] (2019, April 23). Product Monograph for LUTATHERATM for Canada. Available online: https://pdf.hres.ca/dpd_pm/00049099.pdf.
We searched by its title and found no matching paper.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“It could also be demonstrated that treatment with [177Lu]Lu-DOTA-TATE was safe and well tolerated [8].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 1. Introduction
What the sources say
- Not matchedcites [8] (2019, April 18). Product Monograph LUTATHERA®. Available online: https://www.samnordic.se/wp-content/uploads/2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
We searched by its title and found no matching paper.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Using the concept of PRRT, Lutathera® combines the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors.”
- Also stated in: § 4. Conclusions · plain
“Combining the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, [177Lu]Lu-DOTA-TATE delivers ionizing radiation specifically and selectively to tumor cells expressing SSTRs.”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > Abstract
What the sources say
- Not matchedcites [8] (2019, April 18). Product Monograph LUTATHERA®. Available online: https://www.samnordic.se/wp-content/uploads/2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
We searched by its title and found no matching paper.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 4. Conclusions · plain
12 more claims
Create a free account to see all 39 claims and to verify the 4 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 3
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532 · cited 1×
“The development of these radiolabeled somatostatin ligands was a very long scientific journey that started with the first description of somatostatin more than 45 years ago [10].”
BackgroundPhase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
Krenning, E. P., Breeman, W. A. P., Kooij, P. P. M., Lameris, J. S., Bakker, W. H., Koper, J. W., Ausema, L., Reubi, J. C., & Lamberts, S. W. J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91258-0 · Cited by 625 · cited 1×
“The first radiolabeled SST analog used for imaging was [123I, Tyr3]octreotide in 1989 [12], while early therapeutic studies used [111In]In-DTPA-octreotide in the mid to late 1990s, since other chelated somatostatin ligands were not available [11].”
MethodSomatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0078 · Cited by 466 · cited 1×
“The first radiolabeled SST analog used for imaging was [123I, Tyr3]octreotide in 1989 [12], while early therapeutic studies used [111In]In-DTPA-octreotide in the mid to late 1990s, since other chelated somatostatin ligands were not available [11].”
MethodAntibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
Consensus nomenclature rules for radiopharmaceutical chemistry — Setting the record straight
Coenen, H. H., Gee, A. D., Adam, M., Antoni, G., Cutler, C. S., Fujibayashi, Y., Jeong, J. M., Mach, R. H., Mindt, T. L., Pike, V. W., et al. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.09.004 · Cited by 226 · cited 1×
“In January 2018 (26 January 2018), Lutathera® ([177Lu]Lu-DOTA-TATE (for rules on nomenclature, see [1,2])) was approved by the FDA [3] for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.”
BackgroundElschot, M., Vermolen, B. J., Lam, M. G. E. H., de Keizer, B., van den Bosch, M. A. A. J., & de Jong, H. W. A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055742 · Cited by 209
Targeted α-therapy–past, present, future?
Brechbiel, M. W. (2007) · Dalton Transactions · doi:10.1039/b704726f · Cited by 151
Crystal structure and solution dynamics of the lutetium(III) chelate of DOTA
Aime, S., Barge, A., Botta, M., Fasano, M., Danilo Ayala, J., & Bombieri, G. (1996) · Inorganica Chimica Acta · doi:10.1016/0020-1693(96)05130-4 · Cited by 148
Research works printed but not linked: 3
- Erion, 1999, High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model [abstract], J. Nucl. Med., 40, 223
- Nagy, 2004, Radionuclide Therapy, Handbook of Nuclear Chemistry, Volume 4, 315
- Rolleman, 1996, Inhibition of Renal Uptake of Indium-111-DTPAOctreotide, J. Nucl. Med., 37, 1388
Cited by
Items 201–300 of 426
Stec, G. J., & Wilson, J. J. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216764 · Cited by 10
Snake venom-derived peptides as anticancer candidates: Pioneering next-generation therapies
Almeida, J. R., Pinos-Tamayo, E. A., Mendes, B. D. S., Robles-Loaiza, A. A., Syahputra, R. A., Oliveira, A. G. S., & Ribeiro, R. I. M. D. A. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189479 · Cited by 13
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?
Montella, L., Ottaviano, M., Morra, R. P., et al. (2022) · Cancers · doi:10.3390/cancers14030774 · Cited by 7
Zhou, Z., Zalutsky, M. R., & Chitneni, S. K. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128725 · Cited by 8
Wen, X., Zeng, X., Shi, C., Liu, J., Zhang, Y., Shi, M., Li, J., Chen, H., Zhuang, R., Chen, X. S., et al. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200193 · Cited by 8
Ottolino‐Perry, K., Mealiea, D., Sellers, C., Acuña, S. A., Angarita, F. A., Okamoto, L., Scollard, D. A., Ginj, M., Reilly, R. M., & McCart, J. A. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.04.001 · Cited by 7
“In patients with inoperable disease, PRRT has resulted in a 3–6 year increased survival benefit from the time of diagnosis compared with historically reported data.5 Currently, radiolabeled SS analogs represent the only class of RPs approved for use in North America.52 Metastatic NETs, particularly carcinoid malignanc…”
BackgroundInfluentialFedotova, A. O., Egorova, B. V., Aleshin, G. Y., Zamurueva, L. S., Алиев, Р. А., Posypanova, G. A., Priselkova, A. B., Колотаев, А. В., Khachatryan, D. S., Осипов, В. Н., et al. (2023) · Mendeleev Communications · doi:10.1016/j.mencom.2023.06.009 · Cited by 7
Lucaroni, L., Oehler, S., Georgiev, T., Müller, M., Bocci, M., Luca, R. D., Favalli, N., Neri, D., Cazzamalli, S., & Prati, L. (2024) · Chemical Science · doi:10.1039/d3sc06668a · Cited by 8
Two Step Synthesis of Octreotide-doxorubicin Conjugates Based on Disulfide Bond Linker
Yu, Q.-Y., Meng, M., Yao, J.-F., Du, S., & Qi, Y. (2025) · 化学学报 · doi:10.6023/a25020034 · Cited by 7
VIPoma: Mechanisms, clinical presentation, diagnosis and treatment (Review)
Abdullayeva, L. (2019) · World Academy of Sciences Journal · doi:10.3892/wasj.2019.22 · Cited by 7
Soare, I.-A., Leeuwenkamp, O. R., & Longworth, L. (2021) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00280-9 · Cited by 7
Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer
Grzmil, M., Wiesmann, F., Schibli, R., & Béhé, M. P. (2022) · Cancers · doi:10.3390/cancers15010017 · Cited by 9
Qin, Y., Imobersteg, S., Stephan, F., Blanc, A., Chiorazzo, T., Berger, P., Schibli, R., Béhé, M. P., & Grzmil, M. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264597 · Cited by 9
Fu, H., Du, B., Chen, Z., & Li, Y. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200128110827 · Cited by 7
Njotu, F. N., Ketchemen, J. P., Babeker, H., Henning, N. W., Tikum, A. F., Nwangele, E., Monzer, A., Hassani, N., Gray, B. D., Pak, K. Y., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07011-2 · Cited by 7
Lynch, S. E., Crawford, C. I., Houson, H. A., Omweri, J. M., Pukkanasut, P., Gallegos, C., Whitt, J. D., Jaskula‐Sztul, R., Lapi, S. E., & Sorace, A. G. (2025) · Scientific Reports · doi:10.1038/s41598-025-94578-x · Cited by 11
Practical Considerations for Implementation of177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
Soulek, D. K., Martin, M. E., Mastascusa, N., & Graves, S. A. (2022) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.122.263813 · Cited by 7
Bonazzi, N., Fortunati, E., Zanoni, L., et al. (2024) · Cancers · doi:10.3390/cancers16040701 · Cited by 6
“With the approval of [177Lu][Lu-DOTA 0 -Tyr 3 ]octreotate ([177Lu]Lu-DOTATATE) radioligand therapy [13] as a second-line treatment for patients with metastatic progressive disease on cold somatostatin analogues, in vivo assessment of SST status is crucial for the selection of patients eligible for…”
BackgroundPeptidomimetics design and characterization: Bridging experimental and computer-based approaches
Romagnoli, A., Rexha, J., Perta, N., Cristofano, S. D., Borgognoni, N., Venturini, G., Pignotti, F., Raimondo, D., Borsello, T., & Marino, D. D. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.07.002 · Cited by 11
Kanagasundaram, T., Sun, Y., Lee, K. K., et al. (2024) · Chemical Communications · doi:10.1039/d4cc04165h · Cited by 6
Somatostatin receptor‐linked α‐particle therapy in neuroendocrine tumours
Navalkissoor, S., & Grossman, A. B. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13463 · Cited by 8
Sanwick, A. M., Haugh, K. N., Williams, E. J., Perry, K. A., Thiele, N. A., & Chaple, I. F. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00320-9 · Cited by 6
Production of radionuclides: Cyclotrons and reactors
Benešová, M., & Reischl, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00003-x · Cited by 6
Kunert, J.-P., Fischer, S., Wurzer, A. J., & Wester, H. (2022) · Pharmaceuticals · doi:10.3390/ph15091161 · Cited by 6
Pretze, M., Michler, E., Runge, R., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16111605 · Cited by 6
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
Al‐Toubah, T., Strosberg, J., Johnson, J. E. H., & El-Haddad, G. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1187870 · Cited by 6
Vaghaiwalla, T. M., Ruhle, B. C., Memeh, K., et al. (2020) · Surgery · doi:10.1016/j.surg.2020.04.001 · Cited by 6
Lee, K. K., Chakraborty, M., Hu, A., Kanagasundaram, T., Thorek, D. L. J., & Wilson, J. J. (2024) · Dalton Transactions · doi:10.1039/d4dt02146k · Cited by 6
Towards the Stable Chelation of Radioantimony(V) for Targeted Auger Theranostics
Olson, A. P., Schrage, B. R., Islam, M. F., Fletcher, L. S., Verich, F., Dierolf, M. A., Aluicio‐Sarduy, E., Becker, K. V., Driscoll, D. M., Girish, N., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202423878 · Cited by 7
Yamaguchi, N., Wei, J., & Isomoto, H. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02241-z · Cited by 8
“This clinical research leaded to the approval of 177 Lu for the treatment of SSTR positive GEP-NETs by the EMA (European Medicines Agency) in 2017 and FDA (Food and Drug Administration) in 2018 [12].”
Impact of medical radionuclide discharges on people and the environment
Batlle, J. V. I., Sweeck, L., & Pérez, F. F. (2024) · Journal of Environmental Radioactivity · doi:10.1016/j.jenvrad.2023.107362 · Cited by 5
Perrone, E., Treglia, G., Giancipoli, R. G., Leccisotti, L., Rindi, G., & Rufini, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146551 · Cited by 6
Silva, M. M., Borges‐Canha, M., Salazar, D. A., Neves, J. S., Ferreira, G., Carvalho, D. M., & Duarte, H. (2023) · Cureus · doi:10.7759/cureus.47506 · Cited by 9
“Following these results, [ 177 Lu]Lu-DOTA-TATE was approved by the US Food and Drug Administration in 2018 and the European Medicines Agency in 2017 for the treatment of adults with SSTR-positive gastroenteropancreatic NETs (GEP-NETs) [7].”
InfluentialThe Radiopharmaceutical Chemistry of Metallic Radionuclides
Hu, A., & Wilson, J. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_6 · Cited by 5
Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands
Redfern, J. S. (2020) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2020.08.00313 · Cited by 6
Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome
Alkassis, S., Ali, M. S. E. S., Awadelkarim, A. M., Saad, E., Halboni, A., Alhusain, R., Kamatham, S., & Idris, I. (2022) · Cureus · doi:10.7759/cureus.22392 · Cited by 7
Click Covalent-Targeted Radionuclide Therapy for Prostate Cancer
Yong, W. P., Zhang, S., Zhang, Z., Li, Z., Qin, Y., Qi, X., Wang, D., Zhang, Y., Li, J., Liu, Z., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01515 · Cited by 7
Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals
Ntihabose, C., Handula, M., Piet, A., et al. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00390-3 · Cited by 4
Yu, Q., Yao, J., Meng, M., Zhang, Z., Pang, C., Zhang, Z., Liu, Q., Chen, X., Yu, R., Wang, K., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.006 · Cited by 6
Tang, J., Gong, D., Li, H., & Li, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.039 · Cited by 7
“Lutathera (lutetium ( 177 Lu) oxodotreotide), a notable PDC for neuroendocrine tumors, links a somatostatin analog peptide to a radioisotope, allowing targeted radiation to tumor cells expressing somatostatin receptors 57 .”
Ordas, L., Foster, S., Pham, P., Ollendorff, A. S., Gnanasekar, V., Toulany, M., & Sodji, Q. H. (2026) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkag056 · Cited by 5
177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model
Park, B.-N., An, Y., Kim, S.-M., Lee, S. J., Park, Y., & Yoon, J. (2024) · Antibodies · doi:10.3390/antib13030051 · Cited by 5
Current Advances in PARP1‐Targeted Theranostics
Tong, J., Chen, B., Volpi, T., Li, Y., Ellison, P. A., & Cai, Z. (2025) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4135 · Cited by 5
Chen, H., & Ma, J. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005861 · Cited by 5
Ferrara, R., Zemmour, C., Reichert, T., Ouk, D., Niccoli, P., Maniry-Quellier, J., Brenot-Rossi, I., Charrier, N., & Oziel-Taïeb, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1568243 · Cited by 6
Radiocobalt theranostic applications: current landscape, challenges, and future directions
Sanwick, A. M., & Chaple, I. F. (2025) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2025.1663748 · Cited by 4
Frank, C., Xiao, Z., Allen, K. J. H., Jiao, R., Malo, M. E., & Dadachova, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1662216 · Cited by 4
Need for enrichment of lutetium isotope and design of a laser based separator module
Majumder, A., Pulhani, A. K., Ghosh, A. K., Singh, P., & Maiti, N. (2023) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2023.111038 · Cited by 4
Preparation of [68Ga]GaCl3 Using a Cyclotron
Rodnick, M. E., Sollert, C., Parr, D. C., et al. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3499-8_5 · Cited by 4
Aurilio, M., Esposito, A., Buonanno, M. J., Morisco, A., Maisto, C., Scala, S., & Lastoria, S. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00344-9 · Cited by 4
The Wnt pathway protein Dvl1 targets somatostatin receptor 2 for lysosome-dependent degradation
Carr, H. S., Zuo, Y., & Frost, J. A. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104645 · Cited by 6
Ullrich, M., Brandt, F., Löser, R., Pietzsch, J., & Wodtke, R. (2023) · ACS Omega · doi:10.1021/acsomega.3c02755 · Cited by 5
Frank, C., Salapa, H. E., Allen, K. J. H., Levin, M. C., Dawicki, W., & Dadachova, E. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300751 · Cited by 5
Kamaldeep, Wanage, G., Loharkar, S., Das, T., Basu, S. K., & Banerjee, S. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2021.0340 · Cited by 7
Anti-SSTR2 Antibody-Drug Conjugate for Neuroendocrine Cancer TherapyPreprint
Si, Y., Kim, S., Guenter, R., Ou, J., Lu, Y., Chen, K., Zhang, J., Whitt, J., Carter, A. M., Bibb, J. A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/688184 · Cited by 4
Zhao, R., Lv, J., Li, M., Xu, S., Liang, W., Lin, X., Gu, D., Zeng, G., Jin, W., Yan, Q., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06942-0 · Cited by 3
Encarnação, P. M. C. C., Correia, P. M. M., Mehrdel, B., et al. (2025) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2025.3527874 · Cited by 3
Eddy, M. A., Rush, E., & McAlister, D. R. (2025) · Solvent Extraction and Ion Exchange · doi:10.1080/07366299.2025.2563896 · Cited by 2
Treating Pediatric Oncology Patients: The Emerging Role of Radioligand Therapy
Laetsch, T. W., States, L. J., Lazow, M., et al. (2025) · Cancers · doi:10.3390/cancers17233821 · Cited by 3
“The 177 Lu-DOTATATE mechanism of action has been described previously by Hennrich and Kopka, 2019 [36].”
Glaser, O. M., Goerlach, H., Salek, M. V., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02286 · Cited by 3
Recent advances in peptide-drug conjugates as anticancer agents
Feng, Y., Li, T., Li, S., Liu, Z., Tang, Z., Chen, C., Zhou, C., Lu, T., & Chen, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118482 · Cited by 5
Head-to-head comparison of [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 efficacy in a PDAC mouse model
van der Heide, C. D., Ntihabose, C., Konijnenberg, M., Ma, H., Stuurman, D. C., de Ridder, C., Seimbille, Y., Doukas, M. C., de Blois, E., & Dalm, S. U. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01372-5 · Cited by 4
“…[ 177 Lu]Lu-DOTATATE and [ 177 Lu]Lu-PSMA-617 are clinically approved for TRT of somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs) and prostate specific membrane antigen (PSMA)-expressing metastatic castration-resistant prostate cancer (mCRPC), respectively [7, 8].”
Barakat, A., Santoro, L., Vivien, M., Kotzki, P., Deshayes, E., & Khier, S. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00829-5 · Cited by 3
Small Bowel Neuroendocrine Neoplasms—A Review
Vulasala, S. S., Virarkar, M., Gopireddy, D. R., Waters, R., Alkhasawneh, A., Awad, Z. T., Maxwell, J. E., Ramani, N. S., Kumar, S. P., Onteddu, N. K. R., et al. (2023) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000001541 · Cited by 3
Kanellopoulos, P., Nock, B. A., Krenning, E. P., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030310 · Cited by 3
“The first clinical success of radiolabeled somato-statin analogs in the treatment of neuroendocrine tumors [4] has fostered research toward other peptide-based analogs targeting alternative biomolecular targets overexpressed in a plethora of human tumors [5].”
Velo, A. F., Carter, L. M., Bellamy, M. B., et al. (2025) · Medical Physics · doi:10.1002/mp.17766 · Cited by 3
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac
Fialová, K. O., Ondrák, L., Vlk, M., Kozempel, J., Nováková, K., Nový, Z., Hajduová, K., Hajdúch, M., Petřík, M., Pruszyński, M., et al. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00337-8 · Cited by 5
Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cells
Damiana, T. S. T., van den Brink, L., Bruin, L. D. K.-D., et al. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01302-x · Cited by 3
Isolation of a Natural Killer Group 2D Small‐Molecule Ligand from DNA‐Encoded Chemical Libraries
Plaza, S. D., Galbiati, A., Migliorini, F., Comacchio, C., Oehler, S., Prati, L., Scheuermann, J., Cazzamalli, S., Neri, D., Bassi, G., et al. (2022) · ChemMedChem · doi:10.1002/cmdc.202200350 · Cited by 3
Kupitz, D., Einspänner, E., Wissel, H., et al. (2022) · Medical Physics · doi:10.1002/mp.15951 · Cited by 3
Okwundu, N., Weil, C. R., Soares, H. P., Fine, G., & Cannon, D. M. (2023) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1074948 · Cited by 6
Durma, A. D., Saracyn, M., Kołodziej, M., Jóźwik−Plebanek, K., Dmochowska, B., Mróz, A., Żmudzki, W., & Kamiński, G. (2023) · Pharmaceuticals · doi:10.3390/ph16091205 · Cited by 3
Dosimetry in Radiopharmaceutical Therapy
Carter, L. M., & Kesner, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_8 · Cited by 4
Vaccarin, C., Mapanao, A. K., Deberle, L. M., Becker, A. E., Borgna, F., Marzaro, G., Schibli, R., & Müller, C. (2024) · Cancers · doi:10.3390/cancers16071262 · Cited by 4
Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2
Xu, W., Langhans, S. A., Johnson, D. K., Stauff, E., Kandula, V. V. R., Kecskemethy, H. H., Averill, L. W., & Yue, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179419 · Cited by 4
Neuroendocrine tumors and diabetes mellitus: which treatment and which effect
Mazzilli, R., Zamponi, V., Mancini, C., Giorgini, B., Golisano, B., Mikovic, N., Pecora, G., Russo, F., Martiradonna, M., Paravani, P., et al. (2025) · Endocrine · doi:10.1007/s12020-024-04149-9 · Cited by 4
Radioligand Theranostics in the Management of Neuroendocrine Tumors
Harris, A. G., Vinik, A. I., O’Dorisio, T. M., & O'Dorisio, M. S. (2020) · Pancreas · doi:10.1097/mpa.0000000000001546 · Cited by 3
“improved sensitivity and specificity and led to the first FDA and European Medicines Agency radiopharmaceutical for PRRT.(32) We should highlight that the most recent enhancement in somatostatin receptor-based imaging uses the positron emitter Ga 68 to label various somatostatin analogs to locate NETs using a PET/ CT…”
MethodNew Perspectives for Neutron Capture Radiation Therapy with 7Be. The Chemistry and Biochemistry Gap
Scorciapino, M. A., Nunes, C., Ceccarelli, M., et al. (2021) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2021.19044 · Cited by 3
Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China
Liu, F., Li, P., Xu, J., Zhang, J., Xu, X., Chen, Z., Qiao, Y., Liang, Y., Chen, J., & Song, S. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01185-4 · Cited by 2
Holiski, C. K., Hoekstra, L., Becker, N., et al. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.465869 · Cited by 2
Wang, L., Chapple, D. E., Kuo, H., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18040449 · Cited by 2
“Several 68 Ga-/ 177 Lu-labeled theranostic agents have been used for cancer diagnosis and radiotherapy, such as [ 68 Ga]Ga-/[ 177 Lu]Lu-NeoB and [ 68 Ga]Ga-/[ 177 Lu]Lu-DOTA-TATE [19,20].”
Oumano, M., Wendt, R. E., Botti, J., et al. (2025) · Journal of Applied Clinical Medical Physics · doi:10.1002/acm2.70084 · Cited by 2
Peptide‐Based Biomaterials as a Promising Tool for Cancer Radiotherapy
Wang, Q., Chu, X., & Liu, J. (2025) · Advanced Science · doi:10.1002/advs.202501775 · Cited by 4
Peikin, J. M., Tara, V. K., Johnson, T. R., Barnhart, T. E., Engle, J. W., & Ellison, P. A. (2025) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.112138 · Cited by 2
From diagnosis to treatment: navigating the course for pancreatic neuroendocrine neoplasms
Mastnak, L., & Badovinac, D. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2569992 · Cited by 2
“Already approved in the United States and Europe for advanced, well-differentiated (G1 and G2), SSTR-positive GEP-NENs [204], 177 Lu-DOTA-TATE PRRT also shows promise in G3 pNETs with a Ki-67 index below 55% [205].”
van der Heide, C. D., McMorrow, R., Gama-Franceschi, F., Doukas, M., Mezzanotte, L., & Dalm, S. U. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.109571 · Cited by 2
Obeid, K., Bezverkhniaia, E., Tolmachev, V., et al. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00402-2 · Cited by 2
Peptide–drug conjugates: Emerging strategies in glioma therapy
Yun, D., Mu, L., Liu, J., Zhao, S., Li, C., Zhai, Q., Sun, H., Wu, X., Shi, K., & Fan, W. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109382 · Cited by 2
Computational studies of target-specific radiopharmaceuticals for theranostics
Gervasoni, S. I., Guccione, C., & Malloci, G. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109264 · Cited by 2
Yamane, T., Kazuta, N., Nakashima, K., et al. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00591 · Cited by 2
Asti, M., D’Ambrosio, L., Iorio, V. D., et al. (2021) · Clinical and Translational Imaging · doi:10.1007/s40336-021-00431-2 · Cited by 2
“Oxodotreotide has high affinity for somatostatin subtype 2 receptors, which are overexpressed by most GEP-NET cells but have low expression in normal tissues [1, 2].”
BackgroundMulticomponent Functionalization of the Octreotide Peptide Macrocyclic Scaffold
Vasco, A. V., Ceballos, L. G., Wessjohann, L. A., & Rivera, D. G. (2022) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202200687 · Cited by 2
Ritawidya, R., Palangka, C. R. A. P., Humani, T. S., Susilo, V. Y., Darojatin, I., & Pujiyanto, A. (2022) · INDONESIAN JOURNAL OF PHARMACY · doi:10.22146/ijp.2514 · Cited by 2
“(Hennrich & Kopka, 2019) can be used to perform SPECT imaging in cancer patients (Hennrich & Kopka, 2019).”
BackgroundMethodInfluentialDosimetric analysis of a compartmental model for radioligand uptake in tumor lesions
Galler, M., Chibolela, C., Rogasch, J. M. M., Huang, K., Siefert, J., Schatka, I., & Amthauer, H. (2023) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ace44a · Cited by 3
Gemmell, A., Brown, C., Ray, S., & Small, A. (2023) · Nuclear medicine communications · doi:10.1097/mnm.0000000000001746 · Cited by 2
Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future
Pijeira, M. S. O., Nunes, P. S. G., Chaviano, S. L., Diaz, A. M. A., DaSilva, J. N., Ricci‐Júnior, E., Alencar, L. M. R., Chen, X. S., & Santos‐Oliveira, R. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230818092634 · Cited by 2
Cancer theranostics: recent global advances
Jahani, R., Mosayebnia, M., Mortazavi, S. M., Movahed, M. A., Tabatabaei, M. S., Khajeamiri, Y., Fatehi, D., & Maleksabet, H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15518-5.00023-9 · Cited by 3
An Overview of Structural Framework and Classification of Theranostic Radiopharmaceuticals
Kaur, J., & Mukherjee, M. (2024) · ChemistrySelect · doi:10.1002/slct.202403431 · Cited by 3
eSOMA-DM1, a Maytansinoid-Based Theranostic Small-Molecule Drug Conjugate for Neuroendocrine Tumors
Chapeau, D., Beekman, S., Piet, A., Li, L., de Ridder, C., Stuurman, D. C., & Seimbille, Y. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00413 · Cited by 2
Role of Apoptosis in Cancer: War of the Worlds, Therapeutic Targets and Strategies
Dhara, A., Kaur, R., Chattopadhyay, R., Das, S., Pal, S., & Sen, N. (2024) · Springer eBooks · doi:10.1007/978-981-97-7905-5_9 · Cited by 2
Metadata
- Authors
- Hennrich, U., & Kopka, K.
- Affiliations
- German Cancer Research Center (DE)
- Corresponding author
- Hennrich, Ute
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2019-07-29
- Volume
- 12
- Issue
- 3
- Pages
- 114
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6789871
- OpenAlex
- W2965362447
- Semantic Scholar
- 541d92ea7d4ff1ddec5cefec2755259d1aa26d0e
- Cited by
- 440
- References
- 26
- Citations by year
- 2026: 58 · 2025: 87 · 2024: 88 · 2023: 61 · 2022: 58 · 2021: 46 · 2020: 38 · 2019: 3
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- 177Lu-DOTATATE, lutetium-177, peptide receptor radionuclide therapy, somatostatin receptors, DOTATATE, gastroenteropancreatic neuroendocrine tumors, radiopharmaceuticals, targeted radionuclide therapy, DNA double-strand breaks, cancer cell death
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1 Structure of [177Lu]Lu-DOTA-TATE (Lutathera®). Simplified writing of complexation [18].](https://figures.cochat.ai/paper-figures/b252f6f0df3d4eceb221f630640ad0bc/lutathera-the-first-fda-and-ema-approved-radiopharmaceutical-for-peptide-figure-1.jpg)
![Figure 2 Simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE.](https://figures.cochat.ai/paper-figures/56d8de000b344458a3f6939340017c5b/lutathera-the-first-fda-and-ema-approved-radiopharmaceutical-for-peptide-figure-2.jpg)